Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Elan Makes A $1 Billion Theravance Royalty Play; What Will Investors Say?

Related Content

Elan Prepares For A Buying Spree Now That Biogen Has Taken Over Tysabri

Feb 06 2013

GSK’s <em>Breo Ellipta</em> Approved With COPD Airflow Obstruction, Exacerbation Claims

May 10 2013

COPD Market Snapshot: New Products, Limited Differentiation

May 06 2013

Theravance To Split Into A Royalty Play and An R&D Company

Apr 26 2013

Related Companies

Elan Corporation

Royalty Pharma plc

Innoviva, Inc.

GSK plc

Biogen, Inc.

Additional Topics

Deals Strategy BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window